Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imipenem/cilastatin: rationale for a fixed combination.

S R Norrby

    Reviews of Infectious Diseases
    |July 1, 1985
    PubMed
    Summary

    Cilastatin co-administration significantly increases the urinary recovery of active imipenem by inhibiting its renal metabolism. This combination therapy also prevents imipenem-induced tubular toxicity, enhancing its safety profile.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2004
    Same author

    S Ragnar Norrby--Director General of the Swedish Institute for Infectious Disease Control. Interview by Pam Das.

    The Lancet. Infectious diseases·2002
    Same author

    Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis.

    Scandinavian journal of infectious diseases·2002
    Same author

    Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.

    Chemotherapy·2001
    Same author

    Levofloxacin.

    Expert opinion on pharmacotherapy·2001
    Same author

    Urinary tract infections: disease panorama and challenges.

    The Journal of infectious diseases·2001

    Area of Science:

    • Pharmacology
    • Nephrology
    • Drug Metabolism

    Background:

    • Imipenem is a broad-spectrum antibiotic.
    • Renal metabolism by dehydropeptidase I reduces active imipenem levels.
    • This metabolism exhibits significant intersubject variability.

    Purpose of the Study:

    • To evaluate the effect of cilastatin on imipenem pharmacokinetics and safety.
    • To determine the impact of the imipenem-cilastatin combination on imipenem urinary recovery.
    • To assess the nephroprotective effect of cilastatin against imipenem-induced toxicity.

    Main Methods:

    • Pharmacokinetic analysis of imipenem and cilastatin in healthy volunteers and patients with renal impairment.
    • Measurement of urinary recovery of unchanged imipenem with and without cilastatin.
    • Evaluation of tubular toxicity in rabbits at high imipenem doses, with and without cilastatin.

    Main Results:

    • Cilastatin inhibits imipenem metabolism, increasing urinary recovery of active imipenem to approximately 70%.
    • In renal impairment, cilastatin elimination is slower than imipenem.
    • High-dose imipenem caused tubular toxicity in rabbits, which was prevented by co-administration with cilastatin.

    Conclusions:

    • The combination of imipenem and cilastatin enhances imipenem efficacy through increased urinary recovery.
    • Cilastatin effectively mitigates the nephrotoxic potential of imipenem.
    • Fixed-dose combination therapy is clinically advantageous for optimizing imipenem therapy and safety.

    Related Experiment Videos